首站-论文投稿智能助手
典型文献
SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic
文献摘要:
The record speed at which Chinese scientists identified severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and shared its genomic sequence with the world,has greatly facilitated the development of coronavirus disease(COVID-19)diagnostics,drugs,and vaccines.It is unprecedented in pandemic control history to develop a dozen successful vaccines in the first year and to immunize over half of the global population in the second year,due to the efforts of the scientific community,biopharmaceutical industry,and regulatory agencies worldwide.The challenges are both great and multidimensional due to the rapid emergence of virus variants and waning of vaccine immunity.Vaccination strategies need to adapt to these challenges to keep population immunity above the herd immunity threshold,by increasing vaccine coverage,especially for older adults and young people,and providing timely booster doses with homologous or heterologous vaccine boosts.Further research should be undertaken to develop more effective vaccines against SARS-CoV-2 variants and to understand the best prime-boost vaccine combinations and immunization strategies to provide sufficient and sustainable immune protection against COVID-19.
文献关键词:
作者姓名:
Yiming Shao;Yingqi Wu;Yi Feng;Wenxin Xu;Feng Xiong;Xinxin Zhang
作者机构:
Chinese Center for Disease Control and Prevention,Beijing 102206,China;Changping Laboratory,Beijing 102206,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Policy Science,Central Committee of the Chinese Peasants and Workers Democratic Party,Beijing 100011,China
文献出处:
引用格式:
[1]Yiming Shao;Yingqi Wu;Yi Feng;Wenxin Xu;Feng Xiong;Xinxin Zhang-.SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic)[J].医学前沿,2022(02):185-195
A类:
B类:
SARS,CoV,research,immunization,strategies,improved,control,pandemic,record,speed,which,Chinese,scientists,identified,severe,acute,respiratory,syndrome,coronavirus,shared,its,genomic,sequence,has,greatly,facilitated,development,disease,diagnostics,drugs,vaccines,It,unprecedented,history,dozen,successful,first,year,immunize,half,global,population,second,due,efforts,scientific,community,biopharmaceutical,industry,regulatory,agencies,worldwide,challenges,both,multidimensional,rapid,emergence,variants,waning,immunity,Vaccination,need,adapt,these,keep,above,herd,threshold,by,increasing,coverage,especially,older,adults,young,people,providing,timely,booster,doses,homologous,heterologous,boosts,Further,should,undertaken,more,effective,against,understand,best,prime,combinations,provide,sufficient,sustainable,immune,protection
AB值:
0.630573
相似文献
Safety and immunogenicity of COVID-19 vaccination among liver transplant recipients in China
Qiu-Ju Tian;Man Xie;Ji-Tao Wang;Yi Wang;Bei Zhang;Jin-Zhen Cai;Xiao-Long Qi;Wei Rao-Division of Hepatology,Liver Disease Center,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Organ Transplantation,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Gastroenterology,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;CHESS-COVID-19 Group,Xingtai People's Hospital,Xingtai 054000,China;Department of Clinical Laboratory,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Immunology,Qingdao University Medical College,Qingdao 266000,China;CHESS Center,Institute of Portal Hypertension,The First Hospital of Lanzhou University,Lanzhou 730000,China
The rapid and efficient strategy for SARS-CoV-2 Omicron transmission control: analysis of outbreaks at the city level
Zheng Jin-Xin;Lv Shan;Tian Li-Guang;Guo Zhao-Yu;Zheng Pei-Yong;Chen Yue-Lai;Guan Shi-Yang;Wang Wei-Ming;Zhang Shun-Xian-Department of Nephrology, Ruijin Hospital, Institute of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People’s Republic of China;Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), NHC Key Laboratory of Parasite and Vector Biology, WHO Collaborating Centre for Tropical Diseases, National Center for International Research On Tropical Diseases, National Institute of Parasitic Diseases, Shanghai 200025, People’s Republic of China;Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, People’s Republic of China;Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230032, People’s Republic of China;School of Global Health, Chinese Center for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People’s Republic of China;One Health Center, Shanghai Jiao Tong University–The University of Edinburgh, Shanghai 200025, People’s Republic of China
Knowledge about,attitude and acceptance towards,and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China:A cross-sectional survey
Jing Hong;Xiao-wan Xu;Jing Yang;Jing Zheng;Shu-mei Dai;Ju Zhou;Qing-mei Zhang;Yi Ruan;Chang-quan Ling-School of Traditional Chinese Medicine,Naval Medical University,Shanghai 200433,China;Department of Integrative Oncology,Changhai Hospital,Naval Medical University,Shanghai 200433,China;Department of Oncology,The First Affiliated Hospital,Bengbu Medical College,Bengbu 233010,Anhui Province,China;Department of Nursing,Fuyang Cancer Hospital,Fuyang 236000,Anhui Province,China;Department of Cardiac Rehabilitation,Shanghai First Rehabilitation Hospital,Shanghai 200090,China;Department of Radiation Oncology,Anhui Chest Hospital,Hefei 230022,Anhui Province,China;Department of Anesthesiology,Chaohu Hospital,Anhui Medical University,Hefei 238000,Anhui Province,China
Potential medicinal plants involved in inhibiting 3CLpro activity:A practical alternate approach to combating COVID-19
Fan Yang;Xiao-lan Jiang;Akash Tariq;Sehrish Sadia;Zeeshan Ahmed;Jordi Sardans;Muhammad Aleem;Riaz Ullah;Rainer W.Bussmann-The Medical Center of General Practice,Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital,Chengdu 610041,Sichuan Province,China;Xinjiang Institute of Ecology and Geography,Chinese Academy of Sciences,Urumqi 830041,Xinjiang Uygur Autonomous Region,China;Department of Biological Sciences,University of Veterinary and Animal Sciences,Ravi Campus,Pattoki 55300,Pakistan;Consejo Superior de Investigaciones Científicas,Global Ecology Unit,Centre for Ecological Research and Forestry Applications-Consejo Superior de Investigaciones Cientificas-Universitat Autònoma de Barcelona,Bellaterra,Barcelona 08193,Catalonia,Spain;Centre for Ecological Research and Forestry Applications,Cerdanyola del Vallès 08193,Catalonia,Spain;Department of Pharmacognosy,College of Pharmacy,King Saud University,Riyadh 11451,Saudi Arabia;Department of Ethnobotany,Institute of Botany,Ilia State University,Tbilisi 0105,Georgia
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
Yuqi Zhu;Xinyi Yang;Jingna Xun;Jun Liu;Qing Wen;Yixiao Lin;Xiaoting Shen;Jun Chen;Songhua Yuan;Xiaying Zhao;Jing Wang;Hanyu Pan;Jinlong Yang;Zhiming Liang;Yue Liang;Qinru Lin;Huitong Liang;Min Li;Jianping Liu;Yinzhong Shen;Xiaoyan Zhang;Pengfei Wang;Daru Lu;Chunhua Yin;Jianqing Xu;Shibo Jiang;Hongzhou Lu;Huanzhang Zhu-State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology,Ministry of Education,Institute of Genetics,School of Life Sciences,Fudan University,Shanghai,200438,China;Scientific Research Center,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Fubio(Suzhou)Biomedical Technology Co.,Ltd,Suzou,215300,China;Department of Infectious Diseases and Immunology,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Fudan University,Shanghai,200032,China;Department of Infectious Diseases and Nursing Research Institution,National Clinical Research Center for Infectious Diseases,The Third People's Hospital of Shenzhen,Shenzhen,518112,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。